The young venture firm, which has bet heavily on tech and biotech’s convergence, has now invested in 35 companies and recently saw one of them acquired by AI giant Anthropic.

Original title: “Dimension restocks with $800M to capitalize on AI’s ‘rapid ascent’”

A return to quarterly sales growth boosted shares higher on Tuesday, though a handful of coming study results will have a bigger impact on the company’s long-term outlook.

Original title: “Novartis climbs on upbeat drug sales as key readouts loom”

Anthropic is betting that AI can make a difference in rare disease research. It has launched a new programme through which it is offering selected researchers up to $50,000 in Claude AI credits to explore new treatments, analyse complex data and accelerate scientific discoveries. However, research is often slowed by small patient populations, limited datasets and fragmented medical information, making it difficult to understand how these diseases develop or identify potential treatments. The company believes AI can help bridge these gaps by analysing large volumes of biomedical data, identifying hidden patterns across diseases, summarising scientific literature and generating new hypotheses that researchers can test in the lab. Anthropic has divided the initiative into two tracks. The first is aimed at scientists, clinicians and academic researchers studying the biology and mechanisms behind rare diseases. The second track is aimed at biotechnologists and early-stage biotech companies developing therapies for rare diseases. According to the company, it can take one to two years to move from a confirmed genetic diagnosis to a treatment available for patients. The company has announced a new initiative under its AI for Science programme, under which it will offer selected researchers and early-stage biotech companies up to $50,000 (around Rs 43 lakh) worth of Claude AI credits over six months to help accelerate research into rare genetic diseases. The company says it wants to build a community of researchers working on similar challenges so they can collaborate, share methods and accelerate discoveries together. This particular programme is focused on research around rare diseases, an area where scientific understanding remains limited despite affecting millions of people worldwide.

Original title: “Anthropic is paying researchers up to $50,000 in AI credits to find rare diseases - India Today”

Bristol Myers is the third pharmaceutical company to recently seek Nvidia’s help building a large AI data center. Elsewhere, a Novartis kidney drug gained a leg up on competitors.

Original title: “Bristol Myers to build ‘powerful’ AI factory; Samsung Biologics bids for peptide maker”